Allergen-specific immune system components

Allergen-specific immune system components refers to the collective molecular and cellular machinery that mediates hypersensitivity reactions to specific environmental antigens. This system is characterized by the production of allergen-specific IgE antibodies, which bind to high-affinity FcεRI receptors on mast cells and basophils (Galli et al., 2012, Nature Medicine). Upon allergen exposure, cross-linking of these receptors triggers the release of inflammatory mediators like histamine, leukotrienes, and cytokines such as IL-4, IL-5, and IL-13. These mediators drive the clinical symptoms of allergic diseases such as asthma, allergic rhinitis, and anaphylaxis (Akdis & Akdis, 2014, Nature Reviews Drug Discovery). Therapeutic strategies targeting this system include monoclonal antibodies that neutralize IgE (e.g., omalizumab) or block cytokine pathways (e.g., dupilumab). Additionally, allergen immunotherapy (AIT) seeks to induce long-term immune tolerance by modifying the T-cell and B-cell response to specific allergens (Pelaia et al., 2017, Frontiers in Physiology). Monitoring these components often involves measuring allergen-specific IgE levels or performing skin prick tests to assess sensitivity. While highly effective, therapies modulating these components must be carefully managed due to the risk of systemic allergic reactions or anaphylaxis.

Other names

Allergen-specific immune responseIgE-mediated signaling pathwayType I hypersensitivity mediatorsAllergic cascade components

Drugs targeting these components work by neutralizing allergen-specific IgE, blocking high-affinity IgE receptors, inhibiting Th2-cytokine signaling (IL-4, IL-5, IL-13), or inducing immune tolerance through controlled allergen exposure.